Evidence map›Paper›PMID 30566006›Full record

Trial reportCirculation2018

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.

Johannes F E Mann, Vivian Fonseca, Ofri Mosenzon, Itamar Raz, Bryan Goldman, Thomas Idorn, Bernt Johan von Scholten, Neil R Poulter

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01179048. Cited by 71 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 13 pooled it
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01179048 phase3completed

A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

Ran2010Enrolled9,341Registered outcomes6Posted comparisons20ConditionsDiabetes, Diabetes Mellitus, Type 2Armsliraglutide, Placebo
PMID 28476871PMID 29947247PMID 24176437PMID 30851070PMID 29760228PMID 30508430PMID 30566004PMID 30260088PMID 29903847PMID 25656058PMID 25275271PMID 26855018other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 13 syntheses or guidelines pooled it, 141 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.Clinical journal of the American Society of Nephrology : CJASN · 2020
    Trial
  18. Biologics for cardiovascular diseases: from bench to bedside.Signal transduction and targeted therapy · 2026
    Review
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 5 countries.

Johannes F E MannKuratorium für Dialyse Kidney Center, Munich, Germany (J.F.E.M.).
Vivian FonsecaDivision of Endocrinology, Tulane University Health Sciences Center, School of Medicine, New Orleans, LA (V.F.).
Ofri MosenzonDiabetes Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel (O.M., I.R.).
Itamar RazDiabetes Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel (O.M., I.R.).
Bryan GoldmanNovo Nordisk A/S, Søborg, Denmark (B.G., T.I., B.J.v.S.).
Thomas IdornNovo Nordisk A/S, Søborg, Denmark (B.G., T.I., B.J.v.S.).
Bernt Johan von ScholtenNovo Nordisk A/S, Søborg, Denmark (B.G., T.I., B.J.v.S.).
Neil R PoulterImperial Clinical Trials Unit, Imperial College London, UK (N.R.P.).
Novo Nordisk (Denmark) · DKHebrew University of Jerusalem · ILFriedrich-Alexander-Universität Erlangen-Nürnberg · DENIHR Imperial Biomedical Research Centre · GBTulane University · US

Funding

Louisiana Clinical and Translational Science CenterU54GM104940 · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · 2025 to 2025
$3.9M
NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

backgroundLEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results) results demonstrated cardiovascular benefits for patients with type 2 diabetes mellitus at high cardiovascular risk on standard of care randomized to liraglutide versus placebo. The effect of glucagon-like peptide-1 receptor agonist liraglutide on cardiovascular events and all-cause mortality in patients with type 2 diabetes mellitus and chronic kidney disease is unknown. Liraglutide's treatment effects in patients with and without kidney disease were analyzed post hoc.

methodsPatients were randomized (1:1) to liraglutide or placebo, both in addition to standard of care. These analyses assessed outcomes stratified by baseline estimated glomerular filtration rate (eGFR; <60 versus ≥60 mL/min/1.73 m

resultsOverall, 2158 and 7182 patients had baseline eGFR <60 or ≥60 mL/min/1.73 m

conclusionsLiraglutide added to standard of care reduced the risk for major cardiovascular events and all-cause mortality in patients with type 2 diabetes mellitus and chronic kidney disease. These results appear to apply across the chronic kidney disease spectrum enrolled. CLINICAL

trial registrationURL: https://www.clinicaltrials.gov/ . Unique identifier: NCT01179048.

Indexed as

AgedDiabetes Mellitus, Type 2Double-Blind MethodFemaleHumansHypoglycemic AgentsLiraglutideMaleMiddle AgedMyocardial InfarctionPlacebosRenal Insufficiency, ChronicStrokeSurvival AnalysisUnited KingdomHypoglycemic AgentsLiraglutidePlaceboscardiovascular outcomesdiabetic kidney diseaseLEADERliraglutidetype 2 diabetes mellitus

Identifiers

PMID30566006
PMCPMC6296845
OpenAlexW2903911191

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.